Sangamo Therapeutics, Inc. (SGMOQ)
0.1478
+0.01
(+5.48%)
USD |
OTCM |
Oct 09, 16:00
Sangamo Therapeutics Free Cash Flow (Quarterly) : -19.30M for March 31, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | -19.30M |
| December 31, 2025 | -24.42M |
| September 30, 2025 | -28.56M |
| June 30, 2025 | -18.18M |
| March 31, 2025 | -26.15M |
| December 31, 2024 | -3.503M |
| September 30, 2024 | 11.64M |
| June 30, 2024 | -26.88M |
| March 31, 2024 | -48.66M |
| December 31, 2023 | -53.21M |
| September 30, 2023 | -50.04M |
| June 30, 2023 | -66.25M |
| March 31, 2023 | -76.50M |
| December 31, 2022 | -64.52M |
| September 30, 2022 | -58.03M |
| June 30, 2022 | -59.43M |
| March 31, 2022 | -61.81M |
| December 31, 2021 | -55.57M |
| September 30, 2021 | -64.63M |
| June 30, 2021 | -59.83M |
| March 31, 2021 | -76.50M |
| December 31, 2020 | -8.306M |
| September 30, 2020 | 29.06M |
| June 30, 2020 | 157.07M |
| March 31, 2020 | -22.66M |
| Date | Value |
|---|---|
| December 31, 2019 | -27.60M |
| September 30, 2019 | -43.01M |
| June 30, 2019 | -43.38M |
| March 31, 2019 | -51.10M |
| December 31, 2018 | -67.60M |
| September 30, 2018 | -36.86M |
| June 30, 2018 | 119.29M |
| March 31, 2018 | -20.75M |
| December 31, 2017 | -17.72M |
| September 30, 2017 | -16.38M |
| June 30, 2017 | 55.08M |
| March 31, 2017 | -13.55M |
| December 31, 2016 | -12.52M |
| September 30, 2016 | -17.20M |
| June 30, 2016 | -16.28M |
| March 31, 2016 | -20.61M |
| December 31, 2015 | -9.188M |
| September 30, 2015 | -14.44M |
| June 30, 2015 | -9.023M |
| March 31, 2015 | -3.477M |
| December 31, 2014 | -2.774M |
| September 30, 2014 | -5.862M |
| June 30, 2014 | -8.913M |
| March 31, 2014 | 11.25M |
| December 31, 2013 | -1.374M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -181.32M |
| Oncolytics Biotech, Inc. | -8.066M |
| Sarepta Therapeutics, Inc. | 196.52M |
| Anixa Biosciences, Inc. | -1.77M |
| Mera Pharmaceuticals, Inc. | -- |